HnSaratin
Hirudo nipponia saratin homolog — Cheng 2023 cloning + recombinant production demonstrates collagen-binding antiplatelet activity.
Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Hirudo nipponia saratin homolog — Cheng 2023 cloning + recombinant production demonstrates collagen-binding antiplatelet activity.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
HnSaratin's recombinant antiplatelet activity in rats does NOT establish clinical efficacy. No FDA-approved derivative; H. nipponia is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 12,370 Da
- Source species
- Hirudo nipponia
- Discovered
- 2023 · Cheng B et al.
Biological Targets
- → collagen (vWF / collagen interaction); platelet adhesion
Key Citations
- Cheng B et al. (2023), Gene · PMID 36996929
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.